Cargando…

Tratamiento farmacológico en tiempos de incertidumbre: uso de la hidroxicloroquina/cloroquina en el tratamiento de COVID-19

BACKGROUND AND OBJECTIVES: : In this moments, of extreme gravity in which we find ourselves, and in the uncertainty face about the most effective treatment against COVID-19 disease and with the aim of find the evidence that support the chloroquine/hydroxychloroquine use recommendation to treat COVID...

Descripción completa

Detalles Bibliográficos
Autores principales: Mayayo-Vicente, S., Rodriguez Salvanés, F., Gallego-Arenas, A., Sánchez-Gómez, L.M., Ruiz-López, M., Sierra García, B., Jurado-López, A., Arriola-Bolado, P., Cervera Cano, M., Novella-Arribas, B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedad Española de Médicos de Atención Primaria (SEMERGEN). Published by Elsevier España, S.L.U. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7837044/
https://www.ncbi.nlm.nih.gov/pubmed/32739134
http://dx.doi.org/10.1016/j.semerg.2020.06.016
Descripción
Sumario:BACKGROUND AND OBJECTIVES: : In this moments, of extreme gravity in which we find ourselves, and in the uncertainty face about the most effective treatment against COVID-19 disease and with the aim of find the evidence that support the chloroquine/hydroxychloroquine use recommendation to treat COVID-19 disease, a systematic review of published studies and RCT studies publishes until April 28, 2020 was carried out. MATERIAL AND METHODS: A systematic search was carried out in PubMed with the keywords COVID-19 and their synonyms and hydroxychloroquine/chloroquine. The data selection and extraction was elaborated by two researchers, independently. The results were discussed with a Primary Care physicians clinical group and the results were synthesized using GRADE methodology. RESULTS: A good quality systematic review was found that includes articles with a high risk of bias. And 8 EC launched that will produce results beyond May 2020. CONCLUSIONS: Although the conclusions of the systematic review generate a low confidence in the results, and the clinical variables that show benefit are intermediate variables, the side effects are acceptable and could be minimized with the use of QT lengthening risk tools, so it is could make a weak recommendation in favor of the use of chloroquine/hydroxychloroquine in patients with mild-moderate stage COVID-19.